134 related articles for article (PubMed ID: 38376107)
1. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study.
Nagao A; Deguchi A; Nogami K
Hematology; 2024 Dec; 29(1):2316540. PubMed ID: 38376107
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
3. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
[TBL] [Abstract][Full Text] [Related]
5. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
6. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
[TBL] [Abstract][Full Text] [Related]
7. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.
Santagostino E; Lentz SR; Misgav M; Brand B; Chowdary P; Savic A; Kilinc Y; Amit Y; Amendola A; Solimeno LP; Saugstrup T; Matytsina I
Haemophilia; 2015 Jan; 21(1):34-40. PubMed ID: 25273984
[TBL] [Abstract][Full Text] [Related]
9. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
Takedani H; Hirose J
Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
11. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
12. Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B.
Fukutake K; Taki M; Matsushita T; Sakai M; Takata A; Yamaguchi H; Karumori T
Haemophilia; 2019 Jul; 25(4):e247-e256. PubMed ID: 31168882
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.
Boban A; Hermans C
Expert Rev Hematol; 2020 Apr; 13(4):303-311. PubMed ID: 32153219
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study.
Drillaud N; Cussac V; Bertho PO; Horvais V; Beurrier P; Ternisien C; Rose J; Fouassier M; Babuty A; Trossaërt M
Transfusion; 2023 Dec; 63(12):2321-2327. PubMed ID: 37850587
[TBL] [Abstract][Full Text] [Related]
15. Updates from guardian™: a comprehensive registration programme.
Ozelo MC
Eur J Haematol; 2015 Dec; 95 Suppl 81():22-9. PubMed ID: 26679394
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.
Wu R; Sun J; Xu W; Hu Q; Li W; Xiao J; Yang F; Zeng X; Zeng Y; Zhou J; Matytsina I; Zhang S; Pluta M; Yang R
Ther Clin Risk Manag; 2020; 16():567-578. PubMed ID: 32606716
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
